Introduction: Vandetanib has recently
INTRODUCTION
Medullary thyroid carcinoma (MTC) arises from calcitonin-secreting parafollicular cells of the thyroid and accounts for less than 5% of all thyroid cancers [1] . The 10-year survival rate for patients with MTC is 96% if the disease is treated while the tumor is confined to the thyroid gland [2] . Distant metastases are observed at presentation in 7-23% of patients [1] . Of these, about 40% will die of the disease within 2 years after the diagnosis of distant metastases, whereas about 40% are still alive after 10 years [2] . Altogether, distant metastases are the leading cause of MTC-related death [1] .
Until recently, therapeutic options for rare cases of advanced, unresectable MTC have been limited, but advances in the understanding of the pathogenesis of MTC have led to the development of targeted therapies for this disease. Vandetanib is a once-daily oral tyrosine kinase inhibitor (TKI) that selectively targets the rearranged during transfection (RET) protooncogene, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR) [3, 4] . Vandetanib (Caprelsa Ò , ZD6474; AstraZeneca, Macclesfield, UK) is the first drug approved for the treatment of adult patients with unresectable, locally advanced, or metastatic disease in the United States and
Europe [5, 6] . Long-term treatment with vandetanib has demonstrated a statistically significant longer median progression-free survival versus placebo (30.5 vs 19.3 months; p = 0.001) in this setting [7] . This underscores the need to anticipate and effectively manage therapy-related adverse events (AEs) that will, in turn, promote patient compliance and, therefore, maximize clinical benefit. Based on clinical studies, the most common
In the Phase III Zactima Efficacy in Thyroid
Cancer Assessment (ZETA) study, patients with locally advanced or metastatic MTC were randomized 2:1 to vandetanib 300 mg/day (n = 231) or placebo (n = 100) [7] . Vandetanib treatment led to a significant increase in the primary endpoint of PFS [hazard ratio 0.46, 95% confidence interval (CI) 0.31-0.69, p\0.001, median follow-up 24 months] versus placebo [7] . The median PFS was 19.3 months in the placebo group, compared with a predicted median PFS of 30.5 months for vandetanib [7] .
Vandetanib also demonstrated significantly high rates of objective response (45% versus 13% for placebo; p\0.001), disease control (87% versus 71%; p = 0.001), and calcitonin biochemical response (69% versus 3%; p\0.001) [7] .
Furthermore, vandetanib was also active in patients with sporadic disease and no detectable RET mutations [7] , suggesting that the presence of a RET mutation is not a prerequisite for patients to benefit from treatment [11] . Diarrhea, hypertension, prolongation of the QTc, and fatigue were the most commonly reported (incidence [5%) treatment-emergent grade 3? AEs in the ZETA trial [7] . Additionally, patients required an increase in thyroid hormone replacement (vandetanib, 49.3% vs placebo, 17.2%). Nearly all patients experienced at least one AE and 55% experienced a grade 3 or higher AE [11] . Most AEs occurred 3-6 months after treatment initiation [11] . Despite the frequency of dose reductions [35% (81/231)] needed with vandetanib, only 12% (28/231) of patients discontinued treatment due to AEs [7] . Rash is the most frequently reported dermatologic AE in vandetanib treatment, occurring in more than 45% of vandetanibtreated patients with MTC in the ZETA trial and is second only to diarrhea [7] . Gastrointestinal (GI) AEs included diarrhea (56%), nausea (33%; 11% grade 3?), decreased appetite (21%), vomiting (14%), and abdominal pain (14%) [7] . Fatigue and asthenia were reported by 24%
and 14% of vandetanib-treated patients in ZETA, respectively.
QTc prolongation [500 ms (any grade) was reported by 14% of vandetanib-treated patients in ZETA versus 1% of those receiving placebo [7] . No cases of Torsades de Pointes (TdP) were reported [7] , although two patients in a wider drug-safety database had QTc intervals [550 ms (one due to sepsis and one due to heart failure) [6] . In a systematic review and meta-analysis involving patients with a range of tumors (n = 2,188), the overall incidence of all-grade and high-grade QTc interval prolongation with vandetanib 300 mg once-daily was 16.4% (95% CI 8.1-30.4%) and 3.7% (95% CI 1.7-7.8%), respectively, among patients with non-thyroid cancer, and 18.0% (95% CI 10.7-28.6%) and 12.0% (95% CI 4.5-28.0%), respectively, among patients with thyroid cancer [12] . Treatment discontinuations due to QTc prolongation (0.9%) and hypertension (0.9%) have been reported [13] .
In this review, we aim to summarize data in the literature on AEs associated with vandetanib therapy and provide community healthcare providers with specific practical guidance on patient education, monitoring, and management of patients taking vandetanib for MTC.
DISCUSSION
The Need for Optimal Management Vandetanib is typically given initially in MTC as a once-daily 300 mg capsule taken with or without food at about the same time each day [5, 6] , which may contribute to patient acceptance and adherence. The prolonged halflife of vandetanib (19 days) is a factor for consideration in the management of any potential AEs [6] ; pharmacokinetic data for the drug are published elsewhere [14] . Local prescribing information should be consulted for full details of dosage and administration guidelines for vandetanib therapy.
Dose reduction may result in rapid AE improvement, suggesting a direct toxic effect of the agent. For grade 3 or 4 AEs, vandetanib is discontinued until AEs resolve, after which vandetanib therapy is resumed at a lower dose.
Efficacy is observed at doses lower than 300 mg/ day [15] , and for long-term treatment finding a dose that is well tolerated and allows a normal quality of life may be the best way to ensure patient compliance and avoid self-made adjustments to medication.
Management of Dermatological AEs
Patients who receive vandetanib are at risk of developing a rash (Fig. 1) . In a systematic review of trials involving 2,961 patients with a range of tumors, including MTC, the incidence of allgrade and high-grade rash/folliculitis associated with vandetanib 300 mg was 46% (95% CI 40.6-51.8%) and 3.5% (95% CI 2.5-4.7%), respectively [16] . The mechanism of the rash has not been fully elucidated, but most observed rashes, especially those presenting as follicular pustules (Fig. 2) , are probably due to the anti-EGFR action of vandetanib, as anti-EGFR agents are associated with acute and subacute folliculitis [17] . It is thought that the ability of vandetanib to block EGFR triggers follicular hyperkeratosis, leading to follicle obstruction and an inflammatory response [18] . There is also a risk of superinfection of these skin lesions. Other cutaneous AEs observed with vandetanib treatment include photosensitivity, xerosis, finger clefts, paronychia, genital skin reactions, subungual splinter hemorrhages, and blue-gray macules [17] . Photosensitivity is observed in all patients, even through glass Collaboration with a dermatologist may be needed in severe or complicated cases.
Questions to consider when dealing with a rash are listed in Table 2 . An extensive review of commonly used topical and systemic therapies to treat skin-related AEs induced by vandetanib is shown in Table 3 [23] [24] [25] [26] .
Management of Cardiovascular AEs
Increased blood pressure and QTc prolongation have been observed in patients taking vandetanib. Based on a systematic review and meta-analysis of 3,154 patients receiving vandetanib, the incidences of all-grade and high-grade hypertension were 24.2% (95% CI 18.1-30.2%) and 6.4% (95% CI 3.3-9.5%), respectively [27] . Patients with MTC also had a Eat small frequent meals (e.g. bananas, rice, apple sauce, toast, plain pasta)
Treatment with loperamide (one pill after each stool) and codeine
For severe diarrhea, vandetanib should be stopped until diarrhea improves and then resumed at a reduced dose [6] For persistent diarrhea after cessation of vandetanib, a stool workup for blood, infectious causes, and fecal leukocytes should be performed if possible Fig. 4 Schematic representation of normal electrocardiographic trace. The QT interval is a measure of the time between the start of the Q wave and the end of the T wave on an ECG trace. Generally speaking, it represents electrical depolarization and repolarization of the left and right ventricles. A prolonged QT interval is a biomarker for ventricular tachyarrhythmias such as Torsades de Pointes and is a risk factor for sudden death. As the QT interval is influenced by heart rate, the relative risk interval preceding the QT interval is measured to correct for this. ECG electrocardiogram [6] . The term ''corrected'' QT interval may be misunderstood. It relates to the QT interval but is adjusted for heart rate (Fig. 4) . Definitions for QTc interval prolongation vary in the literature, and prolongation is characterized either in absolute (e.g. [500 ms) or relative terms (e.g.
[30 ms change from baseline in QTc interval).
In general, an interval of above 480 ms is considered prolonged.
Accurate measurement of the QTc interval is best performed manually, rather than relying on automatic measurements of standard ECG machines, to guide treatment with QTcprolonging drugs [29] . Correction formulae such as Bazett's square root formula (QTc = QT/RR 1/2 ) are frequently used but are often inaccurate at the extremes of physiological heart rate [29] . Use of a QT nomogram, which consists of a plot of QT versus heart rate, is an alternative approach. A QT interval-heart rate pair that plots above an ''at-risk'' line indicates that the patient is at risk of TdP (Fig. 5) In two small studies of patients receiving chemotherapy, palonosetron did not cause severe rhythmic disorders or symptomatic electrocardiogram (ECG) changes [36] , or a statistically significant increase in median QT minimum value [37] . Palonosetron may, therefore, be considered an alternative antiemetic therapy. Nevertheless, caution should be exercised in its concomitant use with medicinal products that increase the QTc interval or in patients who have or are likely to develop prolongation of the QT interval. As palonosetron may increase large bowel transit time, patients with chemotherapy-induced diarrhea could benefit from this substance [34] .
Management of Gastrointestinal AEs
The antiemetic action of metoclopramide is based on its D2 receptor antagonist activity.
However, at higher doses the substance also exerts 5-HT3 antagonist activity. Thus, metoclopramide may be associated with QTc prolongation and should be used with caution only [38] .
Aprepitant is a neurokinin 1 (NK1) receptor antagonist that is available for chemotherapyinduced nausea and vomiting [39] . Signals indicating QT-prolonging properties could not be derived so far from 15 pharmacologic studies [40] .
Diarrhea, either due to the disease or treatment, can impair quality of life in patients with MTC, resulting in dose reduction, interruption, or discontinuation of therapy. It may also put patients at risk of dehydration with electrolyte disturbance and other potentially life-threatening complications due to the QTc prolongation associated with vandetanib. Diarrhea frequently worsens during antibiotic therapy that may be given for folliculitis.
Diarrhea may also exist in MTC because of the production of hormones that accelerate gastrointestinal motility and may improve with vandetanib treatment. In addition, the use of agents that slow peristaltic movements (e.g. loperamide) or mild opioids (e.g. codeine) can provide relief that is usually partial.
Evidence on the efficacy of somatostatin analogs against diarrhea in patients with MTC is not available.
As with other types of AEs, awareness and education regarding GI tolerability is a key part of patient education. Typical measures to take when confronted with diarrhea are listed in Table 2 . QTc prolongation can also occur with hypokalemia; therefore, regular monitoring of serum electrolytes is essential. In case of severe GI symptoms, vandetanib should be stopped 
Management of Generalized AEs
The effect of generalized AEs on quality of life can vary. While many patients are able to maintain normal activity schedules, others experience debilitating fatigue that leads to dose limitation or treatment discontinuation [13] . Vandetanib treatment in patients with MTC increases visceral fat and muscle body content, in contrast to other TKIs [41] . This positive effect should be taken into consideration and patients on vandetanib should be encouraged to follow a normal social and professional life, and participate in sports activities. It is worth noting that pregnancy constitutes a contraindication for vandetanib therapy and effective contraception is necessary for all patients.
Other AEs reported with vandetanib therapy include reversible posterior leukoencephalopathy syndrome, which requires treatment withdrawal, and cornea verticillata, which is responsible for blue vision and regresses with dose reduction [5] . Apart from providing vital patient education (Table 2) , specialist nurses are typically faced with the challenges of eliciting AE information from patients. While some patients may feel more comfortable discussing AEs with a nurse rather than a physician, not all patients realize the importance of reporting specific symptoms and they may not contact the clinic if they experience AEs during treatment. Therefore, it is important that patients are made aware, often by the specialist nurse, of symptoms to look out for and the value of reporting at an early stage.
A list of drugs that should be avoided during vandetanib treatment should be given to the patient so that any care provider can check whether a drug can be safely given or not and, in case of doubt, contact a specialist nurse or physician. In addition, patients must be made aware of the importance of informing their specialist nurse and/or physician of any concomitant medication started by other clinicians for comorbidities. These should be carefully documented and cross-checked to avoid possible dangerous drug interactions.
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